IMPACT BIOMEDICINES
Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera.
IMPACT BIOMEDICINES
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.impactbiomedicines.com
Total Employee:
5001+
Status:
Active
Contact:
858-221-0950
Total Funding:
112 M USD
Technology used in webpage:
Starfield Technologies Proofpoint CSC Global DNS
Similar Organizations
CorVent Medical
CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care.
Options MD
Options MD helps patients with treatment-resistant mental illnesses access better-performing treatments, faster.
Sirenas Marine Discovery
A Biomedical research organization
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
University Ambulatory Surgery Center
UASC focuses on providing the highest level of care and communication to our patient, physician specialists and their staff.
Current Advisors List
Current Employees Featured
Founder
Investors List
Oberland Capital
Oberland Capital investment in Debt Financing - Impact Biomedicines
Medicxi
Medicxi investment in Series A - Impact Biomedicines
Official Site Inspections
http://www.impactbiomedicines.com
- Host name: 165.160.15.20
- IP address: 165.160.15.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Impact Biomedicines"
Impact Biomedicines Inc - Company Profile and News
Impact Biomedicines, Inc. operates as a biotechnology company. The Company focuses on development of life-changing treatments for patients with myeloproliferative neoplasms and …See details»
Celgene to Acquire Impact Biomedicines, Adding …
Jan 7, 2018 Celgene: Investors: Patrick E. Flanigan III, (908) 673-9969 Corporate Vice President Investor Relations or Media: Brian P. Gill, 908) 673-9530 Vice President Corporate Communications or Impact ...See details»
Organization | Impact Biomedicines
Impact Biomedicines Report issue For profit Phase 1 Founded: San Diego CA United States (2016)See details»
Impact Biomedicines Company Profile 2024: Valuation, …
Impact Biomedicines General Information Description. Developer of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The company's drugs focus on fedratinib, an oral small molecule kinase inhibitor …See details»
Celgene to buy Impact Biomedicines for up to $7 billion
Jan 8, 2018 U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones …See details»
Impact Biomedicines - Funding, Financials, Valuation & Investors
Impact Biomedicines is pioneering the development of life-changing treatments for patients. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»
Impact Biomedicines - Craft
Impact Biomedicines is a company that develops treatments for patients with myeloproliferative neoplasms and other cancers. It is advancing a late-stage pipeline centered around fedratinib, …See details»
Impact Biomedical, Inc. | Reverse Engineering Nature
Impact Biomedical. Impact Biomedical Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc. The company is evaluating strategic options to …See details»
Investors - Impact Biomedical
Overview. Impact Biomedical Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc. The company is evaluating strategic options to accelerate value …See details»
Celgene to Buy Impact Biomedicines | ASH Clinical News
Jan 7, 2018 Celgene agreed to buy Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. Celgene will …See details»
Celgene to Buy Impact Biomedicines for up to $7 Billion
Jan 8, 2018 Celgene will pay an additional $1.4 billion, depending on the receipt of U.S. Food and Drug Administration milestone approvals. Finally, Celgene will make payments depending …See details»
Impact Biomedicines Acquired By Celgene - Pharma's Almanac
Celgene to pay $1.1 billion upfront and up to $5.9 billion in milestone fees. In a move intended to diversify its portfolio, Celgene has agreed to acquire privately held San Diego, California …See details»
Impact BioMedical Inc. (IBO) Company Profile & Overview - Stock …
6 days ago Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for …See details»
Startup Impact Biomedicines Raises $22M to Bring Fedratinib to ...
Oct 13, 2017 Impact Biomedicines launch to pioneer the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Contacts …See details»
Celgene to buy Impact Biomedicines for $1.1bn upfront - Financial …
Jan 8, 2018 Celgene, the acquisitive drugmaker, has agreed to buy Impact Biomedicines for $1.1bn upfront and a further $1.25bn dependent on successful regulatory approvals of the …See details»
J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact ...
Jan 8, 2018 The big biotech says it will spend $1.1 billion upfront for Impact Biomedicines, a tiny startup that got a $22 million series A just three months ago (and later around $90 million in …See details»
Everyone Goes Home with a Balloon - Impact Biomedicines
Yesterday, we announced the acquisition of Impact Biomedicines by Celgene in a deal valued at up to $7bn. This is obviously good for the Impact Biomedicines shareholders and is a fantastic …See details»